Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC)

被引:23
|
作者
Neuhaus, Jochen [1 ]
Schulte-Baukloh, Heinrich [2 ]
Stolzenburg, Jens-Uwe [1 ]
di Fenizio, Pietro Speroni [3 ]
Horn, Lars-Christian [4 ]
Rueffert, Henrik [5 ]
Hartenstein, Siegurd [1 ]
Burger, Maximilian [6 ]
Schulze, Matthias
Schwalenberg, Thilo [1 ]
机构
[1] Univ Hosp Leipzig, Dept Urol, D-04103 Leipzig, Germany
[2] Charite, St Hedwig Hosp, Sch Med, Dept Urol, D-13353 Berlin, Germany
[3] Univ Coimbra, Dept Informat Engn, CISUC, Coimbra, Portugal
[4] Univ Leipzig, Dept Pathol, Leipzig, Germany
[5] HELIOS Hosp Borna, Dept Anesthesiol Intens Care Pain Therapy & Palli, Borna, Germany
[6] Univ Regensburg, Dept Urol, Caritas Hosp St Josef, Regensburg, Germany
关键词
Interstitial cystitis; Muscarinic receptors; Purinergic receptors; Histamine receptors; Detrusor smooth muscle cells; Confocal immunofluorescence; Real-time PCR; INTERSTITIAL CYSTITIS; MUSCARINIC RECEPTORS; SIGNAL-TRANSDUCTION; M-2; EXPRESSION; CELLS;
D O I
10.1007/s00345-011-0774-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose Dysregulation of neurotransmitter receptors may contribute to bladder overactivity (OAB) symptoms. To address the question whether specific receptor expression patterns are associated with bladder pain syndrome/interstitial cystitis (BPS/IC), we examined the expression of muscarinic, purinergic and histamine receptors in the detrusor. Methods Detrusor receptor expression was investigated in bladder biopsies of female BPS/IC patients (n = 44; age 60.64 +/- 13.78, mean +/- SD) and carcinoma patients (n = 11; age 58.91 +/- 12.72) undergoing cystectomy. Protein expression of muscarinic (M2, M3), purinergic (P2X1-3) and histamine receptors (H1, H2) was analysed by confocal immunofluorescence, and gene expression was quantified by real-time polymerase chain reaction (qPCR). Results M2, P2X1, P2X2 and H1 receptor immunoreactivity (-IR) was significantly enhanced in BPS/IC compared to the control group, while there was no difference for M3-, P2X3- and H2-IR. We calculated a score, which separated BPS/IC from control patients with an AUC of 89.46%, showing 84.09% sensitivity and 90.91% specificity. Patients had a 9.25 times enhanced calculated risk for BPS/IC. In addition, two patient subgroups (M2 > M3 and M3 > M2) were observed, which differed in associated purinergic and histamine receptor expression. Conclusions M2, P2X1, P2X2 and H1 were significantly upregulated in BPS/IC patients, and H2 was occasionally highly overexpressed. There was no significant correlation between receptor protein and gene expression, implying posttranslational mechanisms being responsible for the altered receptor expressions. On the basis of individual receptor profiles, upregulated receptors could be targeted by monotherapy or combination therapy with already approved receptor inhibitors, thereby promoting tailored therapy for patients suffering from BPS/IC-like symptoms.
引用
收藏
页码:693 / 700
页数:8
相关论文
共 50 条
  • [1] Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC)
    Jochen Neuhaus
    Heinrich Schulte-Baukloh
    Jens-Uwe Stolzenburg
    Pietro Speroni di Fenizio
    Lars-Christian Horn
    Henrik Rüffert
    Siegurd Hartenstein
    Maximilian Burger
    Matthias Schulze
    Thilo Schwalenberg
    World Journal of Urology, 2012, 30 : 693 - 700
  • [2] Interstitial cystitis/bladder pain syndrome (IC/BPS)
    Vahlensieck, Winfried
    UROLOGIE, 2023, 62 (06): : 582 - 589
  • [3] Interstitial cystitis/bladder pain syndrome (IC/BPS)
    Bschleipfer, Thomas
    UROLOGE, 2020, 59 (09): : 1123 - 1134
  • [4] Interstitielle Zystitis/Blasenschmerzsyndrom (IC/BPS)Interstitial cystitis/bladder pain syndrome (IC/BPS)
    Winfried Vahlensieck
    Die Urologie, 2023, 62 (6) : 582 - 589
  • [5] Hydrodistention of the bladder for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC)
    Hoke, Tanya P.
    Goldstein, Howard
    Saks, Emily K.
    Vakili, Babak
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (03) : 784 - 786
  • [6] Rehabilitation of patients with interstitial cystitis/bladder pain syndrome (IC/BPS)
    Vahlensieck, Winfried
    El Idrissi, Raschid
    Gerhard-Franke, Ursula
    Huber, Maren
    Jenner, Jennifer
    Zermann, Dirk-Henrik
    AKTUELLE UROLOGIE, 2021, 52 (06) : 575 - 582
  • [7] Investigational drugs for bladder pain syndrome (BPS)/interstitial cystitis (IC)
    Chuang, Yao-Chi
    Chermansky, Christopher
    Kashyap, Mahendra
    Tyagi, Pradeep
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 521 - 529
  • [8] Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS)
    Ogawa, Teruyuki
    Ishizuka, Osamu
    Ueda, Tomohiro
    Tyagi, Pradeep
    Chancellor, Michael B.
    Yoshimura, Naoki
    EXPERT OPINION ON EMERGING DRUGS, 2015, 20 (04) : 555 - 570
  • [9] THE MICROBIOME OF HUNNER LESIONS IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS)
    Nickel, J. Curtis
    Erhlich, Garth
    Doiron, R. Christopher
    Kelly, Kerri-Lynn
    Earl, Joshua
    JOURNAL OF UROLOGY, 2020, 203 : E1163 - E1164
  • [10] Intravesical tacrolimus in intractable bladder pain syndrome/interstitial cystitis (BPS/IC)
    Mishra, Nagendra Nath
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 84 - 84